Latest stories on AVIR
Atea drops despite late-stage trial win for hepatitis C therapy
Seeking Alpha42 · neutralproduct/pr
Atea’s BEM/RZR Achieves High Cure Rates Across HCV Genotypes—Potential to Shorten Treatment for Majority of Patients
July 28, 2026
MarketChameleon76 · bullishproduct/pr
Atea Pharmaceuticals, Inc. (AVIR) files 8-K
SEC 8-K50 · neutralgeneral
Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst
Seeking Alpha63 · neutralproduct/pr
AVIR: [Form 4] Atea Pharmaceuticals, Inc. Insider Trading Activity
StockTitan SEC50 · neutralgeneral